Shots:
- The US FDA has approved AstraZeneca‘s Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate or BGF 320/36/9.6μg) for the maintenance treatment of asthma in pts (≥12yrs.); regulatory review is ongoing in the EU, Japan & China
- Approval was based on the P-III (LOGOS & KALOS) trials evaluating Breztri Aerosphere vs PT009, Symbicort, and PT009 + Symbicort in ~4,300 pts with uncontrolled asthma
- In trials, Breztri Aerosphere improved lung function vs dual ICS/LABA & showed rapid onset, with significant improvement from baseline within 5 min. of the first dose; full results were published in The Lancet Respiratory Medicine
Ref: AstraZeneca | Image: AstraZeneca | Press Release
Related News: AstraZeneca Reports FDA Approval of Saphnelo for Systemic Lupus Erythematosus (SLE)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
